At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
BYL-719 (alpelisib) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating BYL-719 (alpelisib) and Nab-paclitaxel for Breast Cancer. Completed, enrolled 43 participants across 4 sites.
Detailed Summary
Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedMar 2015
Primary CompletionSep 2017
Study CompletionMar 2022
TodayJul 2026
First PostedMar 4, 2015
Enrollment StartFeb 1, 2015
Primary CompletionSep 21, 2017
Study CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.3 years ago
Interventions
BYL-719 (alpelisib)drug
Oral PI3K inhibitor
Nab-paclitaxeldrug
IV taxane